Sam Kintz, M.B.A., is the President and Chief Executive Officer at ENLIVEN THERAPEUTICS INC, a biotechnology company focused on developing novel small molecule kinase inhibitors for the treatment of cancer. With an extensive background in the biopharmaceutical industry, Kintz brings a wealth of experience and leadership to his role at ENLIVEN. He holds an M.B.A. from a prestigious business school, which has equipped him with the strategic and financial acumen necessary to guide the company through the complex landscape of drug development and commercialization. Prior to joining ENLIVEN THERAPEUTICS INC, Kintz held several key positions at renowned biopharmaceutical companies, where he played a pivotal role in driving the growth and success of various oncology programs. His expertise in business development, strategic planning, and team leadership has been instrumental in advancing innovative therapies from the laboratory to the clinic. Under his guidance, ENLIVEN has made significant strides in its mission to develop targeted therapies that address unmet medical needs in cancer treatment. As President and CEO, Kintz is responsible for overseeing the overall direction and operations of ENLIVEN THERAPEUTICS INC. He works closely with the company's scientific team to ensure that research and development efforts are aligned with the organization's goals and objectives. Kintz's visionary leadership and commitment to improving patient outcomes have positioned ENLIVEN as a promising player in the field of oncology drug development. His dedication to fostering a culture of innovation and collaboration within the company has been a driving force behind ENLIVEN's progress and growth.